

Special Issue

Antimycobacterial Agents: Combating Drug-Resistant Tuberculosis

Message from the Guest Editor

Tuberculosis (TB) remained the leading cause of death caused by infection until it was overtaken by SARS-CoV-2. The causative agent, *Mycobacterium tuberculosis*, is known to be highly effective in staying dormant within the human host, and when the time is right—often coinciding with the host's immune system being compromised—it will cause the development of the disease phenotype. Similarly to what we have witnessed with the resistance observed for COVID-19 variants, multi-drug- and extensively drug-resistant forms of TB necessitate novel treatment and preventative options. A lot still needs to be uncovered regarding aspects of TB host-bacteria interplay and combating the resistant forms. The vaccine has played a key role in providing immunity worldwide since its discovery around a century ago. However, much like what we have seen with COVID-19 vaccines, both preventative and treatment options are crucial for healthcare. This is when medicinal chemists and pharmacologists from academic, open-source and pharma settings have a role to play: small-molecule drugs will continue to provide essential ammunition for human medicine.

Guest Editor

Dr. Hendra Gunosewoyo

Faculty of Health Sciences, Curtin Medical School, Curtin University,
Perth, Australia

Deadline for manuscript submissions

closed (30 April 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/143247

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)